Similarly, myeloid immune modulation was also observed in the 4T1 and CT26 tumor models, with a decrease in the CD11b+ myeloid subsets, specifically in F4/80+ macrophages and cDC2 cells (Supplementary Figure 11). This evidence concerns the gene ITGAM and neoplasm.